-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On September 16, Pfizer announced the recall of all batches of Chantix (Chinese trade name: Changpei, generic name: varenicline, varenicline tartrate) 0.
5mg and 1mg tablets in the United States due to excessive carcinogenic substances
.
Pfizer said in a statement that it took this action because it detected that the carcinogen nitrosamine (N-nitroso-varenicline) reached or exceeded the acceptable level set by the FDA
.
There are already alternative suppliers approved in the United States
.
Pfizer added that although long-term intake of nitrosamines may theoretically increase the risk of cancer in humans, there is no immediate risk for patients taking this drug
.
He also stated that the health benefits of quitting smoking outweigh the theoretical potential carcinogenic risk of nitrosamine impurities in varenicline
.
In June of this year, the US pharmaceutical giant stopped Chantix’s global sales and pointed out that the content of nitrosamines exceeded the “acceptable” daily intake
In 2020, Chantix generated sales of US$919 million for Pfizer, a year-on-year decrease of approximately 17.